Answers are grounded in this paper and cite their sources.
Post hoc analysis compares outcomes in alternative donor HSCT, revealing mPTCy may reduce GVHD, indicating potential benefits for SAA patients.
Post-transplantation cyclophosphamide (PTCy) and granulocyte colony-stimulating factor/anti-thymocyte globulin (G-CSF/ATG) are established protocols for alternative donor haematopoietic stem cell transplantation (AD-HSCT) in severe aplastic anaemia (SAA). A modified PTCy (mPTCy) regimen, featuring increased ATG dosing (2.0 mg/kg/day, days -5 to -3) and reduced cyclophosphamide (40 mg/kg/day, days +3 and +4), showed promising outcomes in a prospective study but lacks direct comparison with G-CSF/ATG. This post hoc comparative analysis utilized data from our prospective mPTCy cohort (ChiCTR2000038297, n = 101, plus a 1-year protocol-consistent enrolment extension, n = 56) and a retrospective historical G-CSF/ATG cohort (n = 140) to compare outcomes in AD-HSCT. Both protocols showed similar incidences of engraftment, graft failure and overall survival. Multivariate analysis confirmed reduced risks of 100-day grade II-IV acute graft-versus-host disease (GVHD) (hazard ratio [HR] 0.43, 95% confidence interval [CI] 0.26-0.71, p < 0.001) and 2-year chronic GVHD (HR 0.33, 95% CI 0.17-0.65, p = 0.001), and improved 2-year GVHD, relapse/rejection-free survival (GRFS; HR 0.51, 95% CI 0.32-0.83, p = 0.007) with mPTCy versus G-CSF/ATG. Subgroup analysis revealed superior outcomes with mPTCy in haploidentical-HSCT, while outcomes were comparable between protocols in unrelated donor HSCT. These findings suggest mPTCy superiority over G-CSF/ATG in SAA patients undergoing AD-HSCT, especially haploidentical-HSCT, by reducing GVHD and improving GRFS.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: